Junctional adhesion molecular 3 (JAM3) is a novel tumor suppressor and improves the prognosis in breast cancer brain metastases via the TGF-β/Smad signal pathway
- 25 September 2024
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 170 (2) , 331-345
Abstract
Purpose Breast cancer brain metastasis (BCBM) is a deadly clinical problem, and the exact underlying mechanisms remain elusive. Junctional adhesion molecule (JAM), a tight junction protein, is a key negative regulator of cancer cell invasion and metastasis. Methods Junction adhesion molecule 3 (JAM3) expression in breast cancer was analyzed using bioinformatics methods and confirmed by PCR, western blotting, and immunofluorescence (IF) in cell lines. The effects of exogenous expression of JAM3 using lentiviral vectors on invasion, adhesion, and apoptosis were verified using transwell assays and flow cytometry. Differentially expressed genes (DEGs) were detected by RNA sequencing and verified by q‒PCR and Western blotting. The effect of JAM3 silencing using siRNA was assessed by an adhesion assay. Kaplan‒Meier analysis was applied to calculate the impact of JAM3 expression and classic clinicopathologic characteristics on survival. Results Bioinformatics analysis revealed that JAM3 expression was reduced in BCBM. Exogenous expression of JAM3 minimizes the ability of breast cancer cells to invade and adhere and promotes their apoptosis. Silencing JAM3 results in morphology changes and the recovery of invasion and adhesion to ECMs, and the TGF-β/Smad signaling pathway may be involved. JAM3 predicts less metastasis and good survival in patients with BCBM. Statistical analysis of BCBM samples detected by immunohistochemistry (IHC) and the associated clinicopathological characteristics revealed that low levels of JAM3 expression and high levels of TNF-β1 are linked to the clinical progression of both primary and metastatic breast tumors. Kaplan–Meier analysis revealed that a high expression level of JAM3 was associated with longer survival. Conclusion JAM3 can serve as a key negative regulator of breast cancer cell invasion, apoptosis, and brain metastasis, possibly through the TGF/Smad signaling pathway. JAM3 is anticipated to be a promising biomarker for the diagnosis and prognosis of breast cancer.Keywords
All Related Versions
Funding Information
- Natural Science Foundation of Guangdong Province (2022A1515012393)
- The General Program of Medical Scientific Research Foundation of Guangdong (A2016072)
- The Qihang Scientific General Project of Sun Yat-Sen Memorial Hospital (YXQH201803)
- the Key Research and Development Plan Project of Guangzhou (2023B03J0079)
- Cancer Research Wales(WGJ2013), the CardiffChina Medical Scholar-ship (CCMRC2017)
This publication has 38 references indexed in Scilit:
- Expression of Tight Junction Molecules in Breast Carcinomas Analysed by Array PCR and ImmunohistochemistryPathology and Oncology Research, 2011
- A four‐gene methylation marker panel as triage test in high‐risk human papillomavirus positive patientsInternational Journal of Cancer, 2011
- The junctional adhesion molecule JAM-C regulates polarized transendothelial migration of neutrophils in vivoNature Immunology, 2011
- HMME-based PDT restores expression and function of transporter associated with antigen processing 1 (TAP1) and surface presentation of MHC class I antigen in human gliomaJournal of Neuro-Oncology, 2011
- A Homozygous Mutation in the Tight-Junction Protein JAM3 Causes Hemorrhagic Destruction of the Brain, Subependymal Calcification, and Congenital CataractsThe American Journal of Human Genetics, 2010
- Vascular Cell Adhesion Molecule-1 Is a Regulator of Ovarian Cancer Peritoneal MetastasisCancer Research, 2009
- Attenuation of Junctional Adhesion Molecule-A Is a Contributing Factor for Breast Cancer Cell InvasionCancer Research, 2008
- Antibody against Junctional Adhesion Molecule-C Inhibits Angiogenesis and Tumor GrowthCancer Research, 2005
- TGF beta signalling and its role in tumour pathogenesis.Acta Biochimica Polonica, 2005
- mRNA Expression and Transport Characterization of Conditionally Immortalized Rat Brain Capillary Endothelial Cell Lines; a Newin vitroBBB Model for Drug TargetingJournal of Drug Targeting, 2000